Saurabh Dahiya, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · University of Maryland Medical Center. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dahiya’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A140273 · Current
Licensed to practise in California · since 2016 · expires 2027-06-30 · University of Delhi, Maulana Azad Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- University of Maryland Medical CenterBaltimore, MDAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of Maryland Medical System, which runs 13 hospitalsHome of Marlene and Stewart Greenebaum Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 13.31 (11.23 to 15.39) · 3,373 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.333, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for University of Maryland Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative respiratory failure rateComplications and deaths | 13.31 (11.23 to 15.39) · 3,373 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.333 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.76 (0.02 to 1.51) · 2,831 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.87 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 180.76 (155.53 to 206) · 504 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.5 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 93 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.8 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.8 · 222 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.8 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 452 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,934 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.06 to 0.41) · 10,607 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.05 to 0.38) · 11,275 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.38 (2.1 to 4.66) · 5,119 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.6 to 2.4) · 3,028 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.72 (0.74 to 2.7) · 4,283 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.87 (4.22 to 7.52) · 3,266 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.08 (0.83 to 3.32) · 1,178 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.43 (0.04 to 0.82) · 9,810 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.913 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.025 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.594 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.541 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.374 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 192 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.8 · 312 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.7 · 196 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.8 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -19.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 141 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (3.5 to 5.6) · 974 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (8.9 to 12.4) · 974 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 9.2 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.1 · 147 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.3 (10.7 to 19.2) · 293 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 228 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,490 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$48,844
Medicare paid this office $48,844 for 98 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 80 | $29,900 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $11,233 | $104 |
| Long return visit (40+ min) | 15 | $4,421 | $152 |
| New patient visit (60+ min) | 14 | $2,278 | $163 |
Who their Medicare patients are
98 Original Medicare patients in 2024. Average age 71 · Women 54% · Also on Medicaid 21% · Health risk score 2.63. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 66% · Atrial fibrillation 31% · Chronic kidney disease 29% · Coronary heart disease 26% · Depression 24% · Diabetes 23% · Dementia 18% · COPD 13% · Heart failure 12% · Cancer 12%.
The office billed $124,971, Medicare allowed $62,884 and paid $48,844; for 396 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 98 | 396 | 71 | 2.63 | $124,971 | $48,844 |
| 2023 | 57 | 309 | 71 | 2.93 | $114,821 | $36,332 |
| 2022 | 69 | 341 | 66 | 2.79 | $110,171 | $34,937 |
| 2021 | 70 | 438 | 65 | 2.51 | $115,917 | $44,389 |
| 2020 | 59 | 275 | 68 | 3.23 | $64,309 | $22,905 |
| 2019 | 51 | 340 | 70 | 2.81 | $86,684 | $29,010 |
| 2018 | 52 | 299 | 66 | 2.88 | $69,336 | $24,665 |
| 2017 | 13 | 45 | 67 | 1.54 | $7,937 | $3,730 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $17,004 | $110 |
| Long return visit (40+ min) | 24 | $16,422 | $128 |
2022: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $19,706 | $90 |
| Long return visit (40+ min) | 38 | $9,884 | $127 |
2021: 4 services
| Long return visit (40+ min) | 41 | $22,810 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $16,881 | $88 |
| Return visit (30+ min) | 13 | $1,893 | $86 |
| Hospital discharge day management, 30 minutes or less | 11 | $744 | $62 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $9,919 | $90 |
| Long return visit (40+ min) | 20 | $5,646 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,485 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,021 | $168 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,140 | $63 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $12,466 | $86 |
| Long return visit (40+ min) | 24 | $10,342 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,795 | $62 |
| Hospital discharge day management, 30 minutes or less | 11 | $686 | $62 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $11,600 | $83 |
| Long return visit (40+ min) | 14 | $9,266 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,103 | $61 |
Medicaid work
$5,311 in 2024
Medicaid paid $5,311 for 46 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 46 | $5,311 |
| 2024 | 46 | 1 | 17 | $5,311 |
Drugs they prescribed that Part D paid
$61,800
Pharmacies billed $61,800 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
167 generic and 16 brand-name prescriptions · $61,800 in drug cost · 56 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Posaconazole | 12 | $16,783 | $1,399 |
| Sulfamethoxazole-Trimethoprim | 49 | $379 | $8 |
| Acyclovir | 25 | $358 | $14 |
| Ondansetron | 17 | $70 | $4 |
| Allopurinol | 17 | $56 | $3 |
Year by year
| 2024 | 183 | 43 | None | 9% | $61,800 |
| 2023 | 97 | 20 | None | None | $12,557 |
| 2022 | 103 | 18 | 0% (0) | 19% | $339,701 |
| 2021 | 172 | 17 | None | 8% | $167,719 |
| 2020 | 170 | 18 | None | 19% | $262,315 |
| 2019 | 179 | 11 | None | None | $86,824 |
| 2018 | 176 | 14 | None | 12% | $79,103 |
| 2017 | 13 | None | 0% (0) | None | $6,168 |
| 2016 | 47 | 15 | None | None | $12,286 |
| 2015 | 83 | 25 | 19% (16) | 22% | $63,209 |
| 2014 | 84 | 25 | None | None | $10,824 |
| 2013 | 43 | 21 | None | None | $3,729 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Sulfamethoxazole-Trimethoprim | 19 | $199 | $10 |
| Ondansetron | 12 | $101 | $8 |
| Allopurinol | 12 | $39 | $3 |
2022: 1 drug
| Valacyclovir | 25 | $2,152 | $86 |
2021: 2 drugs
| Valacyclovir | 57 | $3,722 | $65 |
| Pantoprazole | 14 | $364 | $26 |
2020: 3 drugs
| Valacyclovir | 21 | $1,693 | $81 |
| Sulfamethoxazole-Trimethoprim | 13 | $106 | $8 |
| Pantoprazole | 13 | $84 | $6 |
2019: 4 drugs
| Atovaquone | 14 | $9,436 | $674 |
| Valacyclovir | 30 | $2,945 | $98 |
| Pantoprazole | 17 | $432 | $25 |
| Sulfamethoxazole-Trimethoprim | 18 | $141 | $8 |
2018: 6 drugs
| Noxafil | 11 | $65,142 | $5,922 |
| Valacyclovir | 25 | $1,409 | $56 |
| Triamcinolone Acetonide | 19 | $364 | $19 |
| Sulfamethoxazole-Trimethoprim | 21 | $110 | $5 |
| Ranitidine | 14 | $79 | $6 |
| Carvedilol | 11 | $39 | $4 |
2015: 2 drugs
| Anastrozole | 16 | $1,290 | $81 |
| Oxycodone | 11 | $178 | $16 |
2014: 2 drugs
| Anastrozole | 23 | $1,794 | $78 |
| Hydrocortisone | 11 | $125 | $11 |
Money from drug and device companies
$40,588 in 2025
| 2025 | 7 | 26 | $38,340 | $40,588 |
| 2024 | 6 | 31 | $22,260 | $33,267 |
| 2023 | 5 | 19 | $9,744 | $11,694 |
| 2022 | 5 | 8 | $4,420 | $4,834 |
| 2021 | 1 | 2 | $1,845 | $1,900 |
| 2020 | 1 | 1 | $1,580 | $1,580 |
| 2019 | 2 | 4 | None | $289 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kite Pharma | Yescarta | $17,142 | 15 payments
|
| Janssen Research & Development | Tecvayli | $11,155 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Breyanzi | $6,155 | 3 payments
|
| Novartis Pharmaceuticals | None | $4,200 | 1 payment
|
| Janssen Global Services | None | $1,620 | 1 payment
|
| Celgene | Breyanzi | $251 | 2 payments
|
See all 26 published payments
| Janssen Research & Development | Consulting · 2025-12-10 | Tecvayli | $3,395 |
| Janssen Global Services | Consulting · 2025-10-31 | None | $1,620 |
| Kite Pharma | Meals · 2025-10-23 | Yescarta | $46 |
| Janssen Research & Development | Consulting · 2025-10-03 | Tecvayli | $4,365 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-09-05 | None | $1,910 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-13 | None | $65 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-11 | Breyanzi | $1,380 |
| Novartis Pharmaceuticals | Consulting · 2025-06-10 | None | $4,200 |
| Celgene | Meals · 2025-05-30 | Breyanzi | $28 |
| Celgene | Meals · 2025-05-28 | Breyanzi | $223 |
| Kite Pharma | Meals · 2025-05-21 | Yescarta | $100 |
| Kite Pharma | Consulting · 2025-05-04 | Yescarta | $15,210 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $38 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $53 |
| Kite Pharma | Meals · 2025-05-04 | Yescarta | $67 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $17 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $28 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $58 |
| Kite Pharma | Meals · 2025-05-03 | Yescarta | $127 |
| Kite Pharma | Travel · 2025-05-02 | Yescarta | $427 |
| Kite Pharma | Travel · 2025-05-02 | Yescarta | $757 |
| Kite Pharma | Meals · 2025-04-09 | Yescarta | $2 |
| Janssen Research & Development | Consulting · 2025-04-04 | Tecvayli | $3,395 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-03-27 | None | $2,865 |
| Kite Pharma | Meals · 2025-03-25 | Yescarta | $35 |
| Kite Pharma | Meals · 2025-02-19 | Yescarta | $178 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $33,267
| Gilead Sciences | Yescarta | $12,428 | 5 payments
|
| Kite Pharma | Yescarta | $11,879 | 20 payments
|
| Janssen Research & Development | Tecvayli | $4,608 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $4,152 | 2 payments
|
| Celgene | None | $125 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $75 | 1 payment
|
2023: $11,694
| Kite Pharma | Yescarta | $5,992 | 12 payments
|
| Gilead Sciences | Yescarta | $4,110 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,384 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Epkinly | $123 | 4 payments
|
| Adaptive Biotechnologies | Clonoseq | $85 | 1 payment
|
2022: $4,834
| Incyte | Monjuvi | $4,420 | 2 payments
|
| Kite Pharma | Yescarta | $172 | 3 payments
|
| Adaptive Biotechnologies | None | $136 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $73 | 1 payment
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $33 | 1 payment
|
2021: $1,900
| Incyte | None | $1,900 | 2 payments
|
2020: $1,580
| Kite Pharma | Yescarta | $1,580 | 1 payment
|
2019: $289
| Amgen | Kyprolis | $265 | 2 payments
|
| Seattle Genetics | Adcetris | $25 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kite Pharma, Inc. · Collaborative (Dahiya): Phase Ib, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2025 | Their institution | $876,146 |
| Celgene Corporation · A Phase 2, Open-Label, Single Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of Jcar017 in Adult Subjects With Relapsed Or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (Nhl) · 2022 | Their institution | $670,169 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2025 | Their institution | $371,906 |
| Celgene Corporation · A Phase 2, Open-Label, Single Arm, Multicenter Tri · 2021 | Their institution | $315,427 |
| Kite Pharma, Inc. · A Phase 1b, Investigator- Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High -Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2024 | Their institution | $239,310 |
| Kite Pharma, Inc. · A Phase Ib, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2023 | Their institution | $132,000 |
| Kite Pharma, Inc. · Isr-Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2023 | Their institution | $74,000 |
| Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy C - Relapsed/Refractory Burkitt Lymphoma · 2025 | Their institution | $70,917 |
| Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy C - Relapsed/Refractory Burkitt Lymphoma · 2024 | Their institution | $69,632 |
| Celgene Corporation · Transcend Fl (Indolent Lymphoma) 4l+ Fl, 3l Fl, 2l Fl, 3l+ Mzl (Fol-001) - A Phase 2, Open-Label, Single Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of Jcar017 (Lisocabtagene Maraleucel) in Adult Subjects With Relapsed Or Refra · 2023 | Their institution | $58,476 |
| Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy B - Relapsed/Refractory Richter Transformation · 2023 | Their institution | $43,220 |
| Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy A - Relapsed/Refractory Waldenstrom Macroglobulinemia · 2023 | Their institution | $43,220 |
| Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy D - Relapsed/Refractory Hairy Cell Leukemia · 2023 | Their institution | $43,220 |
| Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2023 | Their institution | $31,182 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Nktr-255 Vs Placebo Following Cd19-Directed Car-T Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma · 2024 | Their institution | $10,040 |
| Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2022 | Their institution | $7,932 |
| JAZZ PHARMACEUTICALS INC. · Outcomes for Hepatic Sinusodial Obstruction Syndrome in Patients Undergoing Stem Cell Transplant: A Nationa-Wide Analysis · 2020 | Their institution | $5,624 |
| Kite Pharma, Inc. · A Phase 1b, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2025 | Their institution | $5,009 |
| Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025 | Their institution | $2,240 |
| Celgene Corporation · A Study To Evaluate the Efficacy and Safety of Jcar017 in Adult Subjects With Relapsed Or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (Nhl) (Transcend Fl) · 2020 | Their institution | $2,113 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2024 | Their institution | $333 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184943730
- Licence
- CA A140273, OH 57.016554California A140273: Current · expires 2027-06-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-05-21
- NPI last updated
- 2022-07-01
- NPI record certified
- 2022-07-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 465 Gypsy Ln Apt 404, Youngstown, OH, 44504